Alterity Therapeutics annual return on equity
2017
2018
2019
2020
2021
2022
Alterity Therapeutics Return on Equity (ROE) Growth & History (ATHE)
Alterity Therapeutics's return on equity was −38.97% for fiscal 2022.
View full Alterity Therapeutics company overviewAlterity Therapeutics annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2022 | 2022-06-30 | −38.97% | +42.42 pp |
| 2021 | 2021-06-30 | −81.39% | +32.15 pp |
| 2020 | 2020-06-30 | −113.53% | −37.92 pp |
| 2019 | 2019-06-30 | −75.61% | −34.04 pp |
| 2018 | 2018-06-30 | −41.57% | −14.17 pp |
| 2017 | 2017-06-30 | −27.40% | — |
Alterity Therapeutics quarterly return on equity
Q2.21
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2021 | 2020-12-31 | 0.00% | — |
Alterity Therapeutics return on equity trends
Over the last five fiscal years, Alterity Therapeutics's return on equity decreased from −27.40% to −38.97%, a change of −11.57 percentage points. The latest reported quarter, Q2 2021, shows 0.00%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Alterity Therapeutics source filings ↗